Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
暂无分享,去创建一个
J C Reubi | J. Laissue | J. Reubi | P. Robberecht | B. Waser | U. Läderach | P Robberecht | B Waser | J O Gebbers | J A Laissue | J. Gebbers | U Läderach | J. Gebbers | Jan-O. Gebbers
[1] P. Robberecht,et al. Development of High Affinity Selective VIP1 Receptor Agonists , 1997, Peptides.
[2] I. Tatsuno,et al. Maxadilan Is a Specific Agonist and Its Deleted Peptide (M65) Is a Specific Antagonist for PACAP Type 1 Receptor , 1998, Annals of the New York Academy of Sciences.
[3] P. Neuhaus,et al. Regulatory peptide receptors in human hepatocellular carcinomas , 1999, Gut.
[4] J. Laissue,et al. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. , 1996, Cancer research.
[5] J. Mueller‐Brand,et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment , 1998, The Lancet.
[6] P. Robberecht,et al. The Long-Acting Vasoactive Intestinal Polypeptide Agonist RO 25-1553 Is Highly Selective of the VIP2 Receptor Subclass , 1997, Peptides.
[7] F. Paraf,et al. Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas , 1996, Journal of cellular physiology.
[8] G. Greenberg,et al. High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes , 1990, Journal of Neuroimmunology.
[9] J C Reubi,et al. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] S. Jiang,et al. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. , 1997, Cancer research.
[11] C. Raftopoulos,et al. Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas. , 1993, The Journal of clinical endocrinology and metabolism.
[12] T. Moody,et al. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. , 1996, Cancer Research.
[13] T. Moody,et al. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Laissue,et al. Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. , 1998, Blood.
[15] S. Rawlings,et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. , 1998, Pharmacological reviews.
[16] J. Laissue,et al. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro‐intestinal adenocarcinoma samples: Where are they really located? , 1999, International journal of cancer.
[17] L. Mazzucchelli,et al. Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. , 1994, Gastroenterology.
[18] R. Valkema,et al. Somatostatin receptor: scintigraphy and radionuclide therapy. , 1996, Digestion.
[19] R. Hauger,et al. N‐Terminal Splice Variants of the Type I PACAP Receptor: Isolation, Characterization and Ligand Binding/Selectivity Determinants , 1999, Journal of neuroendocrinology.
[20] W. Scheithauer,et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. , 1994, The New England journal of medicine.
[21] T. Moody,et al. Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells. , 1995, Cancer research.
[22] S. Said,et al. Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[23] B. Scheithauer,et al. Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas. , 1998, The American journal of pathology.
[24] H. Hashimoto,et al. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. , 1997, Molecular pharmacology.
[25] P. Hof,et al. Autoradiographic mapping of [mono[125I]iodo-Tyr10, MetO17]vasoactive intestinal peptide binding sites in the rat brain , 1987, Neuroscience.
[26] J. Charboneau,et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. , 1990, Cancer research.
[27] J. Brotchi,et al. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors , 1994, Peptides.